Prevention of cell internalization or monomerization of cystatin F by modifying the glycosylation profile or by targeting the peptidase responsible for cystatin F activation could greatly increase the cytotoxic potential of NK cells and improve the existing immunotherapies for cancer patients. The gene discussed is CST7; the disease is cancer.